246 related articles for article (PubMed ID: 35821043)
1. Preliminary outcomes of raltitrexed eluting bead-transarterial chemoembolization using Callispheres® beads for gastrointestinal adenocarcinoma liver metastasis.
Bi Y; Jiao D; Wang Y; Han X; Ren J
World J Surg Oncol; 2022 Jul; 20(1):229. PubMed ID: 35821043
[TBL] [Abstract][Full Text] [Related]
2. Clinical Outcomes of Drug-Eluting Bead Transarterial Chemoembolization Loaded with Raltitrexed for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma.
Bi Y; Jiao D; Ren J; Han X
Can J Gastroenterol Hepatol; 2022; 2022():2602121. PubMed ID: 36051250
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of raltitrexed-eluting CalliSpheres
Sun Z; Jiao D; Fang Y; Liu Y; Xu K; Zhang C; Huang Y; Han X
Ther Adv Med Oncol; 2024; 16():17588359241229661. PubMed ID: 38362379
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes of doxorubicin-eluting CalliSpheres® beads-transarterial chemoembolization for unresectable or recurrent esophageal carcinoma.
Bi Y; Shi X; Ren J; Yi M; Han X; Song M
BMC Gastroenterol; 2021 May; 21(1):231. PubMed ID: 34020608
[TBL] [Abstract][Full Text] [Related]
5. Irinotecan eluting beads-transarterial chemoembolization using Callispheres® microspheres is an effective and safe approach in treating unresectable colorectal cancer liver metastases.
Zhao G; Liu S; Zhang Y; Zhao T; Wang R; Bian J; Wu J; Zhou J
Ir J Med Sci; 2022 Jun; 191(3):1139-1145. PubMed ID: 34264426
[TBL] [Abstract][Full Text] [Related]
6. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
Wu B; Zhou J; Ling G; Zhu D; Long Q
World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773
[TBL] [Abstract][Full Text] [Related]
7. Preliminary outcomes of DEB-TACE loaded with raltitrexed in the treatment of unresectable or recurrent hepatocellular carcinoma.
Bi Y; Wang Y; Zhang W; Lu H; Ren J; Han X
Cancer Imaging; 2023 Feb; 23(1):19. PubMed ID: 36814327
[TBL] [Abstract][Full Text] [Related]
8. Comparison of CalliSpheres
Shi Z; Wang D; Kang T; Yi R; Cui L; Jiang H
Radiol Oncol; 2023 Mar; 57(1):70-79. PubMed ID: 36794998
[TBL] [Abstract][Full Text] [Related]
9. Callispheres® drug-eluting beads transarterial chemoembolization might be an efficient and safety down-staging therapy in unresectable liver cancer patients.
Peng N; Mao L; Tao Y; Xiao K; Yuan G; He S
World J Surg Oncol; 2022 Aug; 20(1):254. PubMed ID: 35941634
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, safety, and prognostic factors of drug-eluting beads transarterial chemoembolization using CalliSpheres in treating huge hepatocellular carcinoma patients.
Wang Z; Mu K; Lv Y; Zhao L; Li B; Hao Y; Wang N
Ir J Med Sci; 2022 Dec; 191(6):2493-2499. PubMed ID: 35064533
[TBL] [Abstract][Full Text] [Related]
11. Transarterial chemoembolization of unresectable renal cell carcinoma with doxorubicin-loaded CalliSpheres drug-eluting beads.
Bi Y; Shi X; Ren J; Yi M; Han X
Sci Rep; 2022 May; 12(1):8136. PubMed ID: 35581365
[TBL] [Abstract][Full Text] [Related]
12. The second-line treatment of hepatocellular carcinoma with CalliSpheres drug-eluting bead transarterial chemoembolization combined with regorafenib: A safety and efficacy analysis.
Liu S; Liu C; Wang Q; Liu Y; Wang D; Zhao G; Yu G
Ir J Med Sci; 2024 Jun; 193(3):1215-1222. PubMed ID: 38300460
[TBL] [Abstract][Full Text] [Related]
13. Pirarubicin-loaded CalliSpheres® drug-eluting beads for the treatment of patients with stage III-IV lung cancer.
Bi Y; Shi X; Yi M; Han X; Ren J
Acta Radiol; 2022 Mar; 63(3):311-318. PubMed ID: 33615822
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of transarterial chemoembolization with drug-eluting beads combined with systemic chemotherapy and targeted therapy in colorectal cancer liver metastasis.
Chen YC; Huang CW; Li CC; Chang TK; Su WC; Chen PJ; Yeh YS; Chang YT; Tsai HL; Shih MP; Wang JY
World J Surg Oncol; 2023 Dec; 21(1):378. PubMed ID: 38041083
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of CalliSpheres® microspheres versus conventional transarterial chemoembolization in the treatment of refractory colorectal cancer liver metastasis.
Li H; Zhang X; Zhao W; Cai F; Qin J; Tian J
BMC Cancer; 2023 Oct; 23(1):970. PubMed ID: 37828491
[TBL] [Abstract][Full Text] [Related]
16. Oxaliplatin Eluting CalliSpheres Microspheres for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma.
Bi Y; Ren K; Ren J; Ma J; Han X
Front Pharmacol; 2022; 13():923585. PubMed ID: 36034827
[No Abstract] [Full Text] [Related]
17. Short-term efficacy and safety of callispheres drug-loaded microsphere embolization in primary hepatocellular carcinoma.
Li J; Wang N; Shi C; Liu Q; Song J; Ye X
J Cancer Res Ther; 2021 Jul; 17(3):733-739. PubMed ID: 34269307
[TBL] [Abstract][Full Text] [Related]
18. Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy and safety.
Zhang ZS; Li HZ; Ma C; Xiao YD
BMC Cancer; 2019 Nov; 19(1):1162. PubMed ID: 31783814
[TBL] [Abstract][Full Text] [Related]
19. Assessment of efficacy and safety by CalliSpheres versus HepaSpheres for drug-eluting bead transarterial chemoembolization in unresectable large hepatocellular carcinoma patients.
Zhao G; Liu S; Chen S; Ren Z; Li C; Bian J; Wu J; Zhou J; Zhang Y
Drug Deliv; 2021 Dec; 28(1):1356-1362. PubMed ID: 34180755
[TBL] [Abstract][Full Text] [Related]
20. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting.
Karalli A; Teiler J; Haji M; Seth E; Brismar TB; Wahlin S; Axelsson R; Stål P
Scand J Gastroenterol; 2019 Jul; 54(7):905-912. PubMed ID: 31287338
[No Abstract] [Full Text] [Related]
[Next] [New Search]
